Li, Fengzhi http://orcid.org/0000-0002-2299-7951
Aljahdali, Ieman A. M.
Zhang, Renyuan
Nastiuk, Kent L.
Krolewski, John J.
Ling, Xiang
Funding for this research was provided by:
Pancreatic Cancer Action Network (20-65-FENG)
Article History
Received: 13 May 2021
Accepted: 21 June 2021
First Online: 12 August 2021
Declarations
:
: This review article contains both animal model data and human cancer cell line data. However, these data for the ethics approval is not applicable.
: The data provided in this review article are from the Authors’ research team and all authors agree to publish these data.
: FL118 and FL118 core structure platform-based analogues will be further developed in Canget BioTekpharma LLC (ExternalRef removed), a spinoff company from Roswell Park Comprehensive Cancer Center (ExternalRef removed). FL, XL are initial investors of Canget for the development of FL118 and FL118 core structure platform-relevant anticancer agents and have Canget equity.